Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Mar 24
8-K
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
7 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
8-K
Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022; Year-to-Date Revenue Increases 45%; Maintains Positive Cash Flow Results
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
1 Jun 23
8-K
Nephros Announces CEO Retirement and Succession Plan
11 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
8-K
Nephros Announces Preliminary Results for First Quarter 2023
4 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Nephros Announces Fourth Quarter and Fiscal Year 2022 Financial Results
8 Mar 23
8-K
Departure of Directors or Certain Officers
3 Feb 23
8-K
Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022
11 Jan 23
8-K
Unaudited Pro Forma Condensed Consolidated Financial Statements
21 Nov 22
10-Q
2022 Q3
Quarterly report
15 Nov 22
NT 10-Q
Notice of late quarterly filing
15 Nov 22
8-K
Third-Quarter Net Revenue of $2.4 Million; Active Customer Sites Increase 18% YoY to a New Record Level
2 Nov 22
8-K
Nephros Announces Agreement to Sell Pathogen Detection Systems Business and Active Customer Sites Increase 18% YoY
11 Oct 22
8-K
Nephros Appoints Joe Harris to Its Board of Directors
8 Sep 22
8-K
Departure of Directors or Certain Officers
23 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Active Customer Sites Climb 21% to New Record
10 Aug 22
8-K
Second Quarter Revenue of $2.9 Million, Year-Over-Year Increase of 27%; Number of Active Customer Sites Climbs 21% Year-Over-Year
6 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
20 May 22
8-K
Nephros Receives FDA 510(k) Clearance for HDF Assist Module
17 May 22
10-Q
2022 Q1
Quarterly report
5 May 22
8-K
Active Customer Sites Climb 17% to New Record
4 May 22
DEF 14A
Definitive proxy
13 Apr 22
10-K
2021 FY
Annual report
3 Mar 22
8-K
Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results
23 Feb 22
8-K
Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2021 and Revenue Guidance for 2022
13 Jan 22
8-K
Changes in Registrant's Certifying Accountant
3 Dec 21
10-Q
2021 Q3
Quarterly report
4 Nov 21
8-K
Nephros Announces Preliminary Results for Third Quarter of 2021
8 Oct 21
424B3
Prospectus supplement
15 Sep 21
Latest ownership filings
4
CHARLES E DAVIDSON
14 Mar 24
4
Arthur H Amron
14 Mar 24
4
Oliver J. Spandow
15 Dec 23
4
Alisa Lask
15 Dec 23
4
Joseph Michael Harris
15 Dec 23
4
Arthur H Amron
15 Dec 23
4
Robert R. Jr. Banks
11 Dec 23
4
Judy Krandel
3 Nov 23
3
Judy Krandel
3 Nov 23
4
Robert R. Jr. Banks
15 Aug 23
3
Robert R. Jr. Banks
17 May 23
SC 13G
Cowen Prime Advisors LLC
3 Feb 23
SC 13G
Cowen Prime Advisors LLC
3 Feb 23
SC 13G
Cowen Prime Advisors LLC
3 Feb 23
4
Alisa Lask
9 Jan 23
4
Oliver J. Spandow
9 Jan 23
4
Tom Gwydir
9 Jan 23
4
Arthur H Amron
9 Jan 23
4
Joseph Michael Harris
9 Jan 23
SC 13G/A
Intelligent Fanatics Capital Management LLC
6 Jan 23
4
Joseph Michael Harris
8 Sep 22
3
Joseph Michael Harris
8 Sep 22
4
Andrew Astor
7 Mar 22
SC 13G
Intelligent Fanatics Capital Management LLC
28 Feb 22
4
Wesley S. Lobo
18 Feb 22
SC 13G
Cowen Prime Services LLC
10 Feb 22
SC 13G
Cowen Prime Services LLC
10 Feb 22
SC 13G
Cowen Prime Services LLC
10 Feb 22
SC 13G
Cowen Prime Services LLC
10 Feb 22
SC 13G
Cowen Prime Services LLC
10 Feb 22
SC 13G
Cowen Prime Advisors LLC
9 Feb 22
SC 13G/A
Samjo Capital LLC
8 Feb 22
4
Alisa Lask
16 Dec 21
4
Tom Gwydir
16 Dec 21
4
Oliver J. Spandow
16 Dec 21
4
Arthur H Amron
16 Dec 21
4
Andrew Astor
16 Dec 21
4
Wesley S. Lobo
3 Sep 21
4
Wesley S. Lobo
23 Aug 21
4
Tom Gwydir
19 Aug 21